secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001654954-22-015279
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q3 revenue $4.78M, net loss $5.0M; cash $158.5M
--------------------------------------------------------

- Total revenue $4.78M (vs $0.02M Q3 2021); gross margin 75%.
- Net loss $5.0M ($0.005/shr) vs $6.35M loss prior year.
- Cash, equivalents, and AFS securities $158.5M at Sep 30, 2022.
- Closed acquisitions of Revo 2 imaging assets and Assisi LOOP/Calmer Canine product lines.
- PulseVet small animal unit sales up 225% YoY; TRUFORMA revenue up 350% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/0001654954-22-015279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-015279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer